(0.36%) 5 118.24 points
(0.42%) 38 401 points
(0.49%) 16 006 points
(-1.66%) $82.46
(4.84%) $2.02
(0.23%) $2 352.60
(0.23%) $27.60
(4.21%) $960.95
(-0.22%) $0.933
(-0.36%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
-0.02% ¥ 4 089.00
Live Chart Being Loaded With Signals
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 3.19M |
Średni wolumen | 4.48M |
Kapitalizacja rynkowa | 6 415.37B |
EPS | ¥0 ( 2024-02-01 ) |
Następna data zysków | ( ¥1.100 ) 2024-05-08 |
Last Dividend | ¥90.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 36.36 |
ATR14 | ¥1.540 (0.04%) |
Wolumen Korelacja
Takeda Pharmaceutical Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Takeda Pharmaceutical Korelacja - Waluta/Towar
Takeda Pharmaceutical Finanse
Annual | 2022 |
Przychody: | ¥4 027.48B |
Zysk brutto: | ¥2 783.41B (69.11 %) |
EPS: | ¥204.29 |
FY | 2022 |
Przychody: | ¥4 027.48B |
Zysk brutto: | ¥2 783.41B (69.11 %) |
EPS: | ¥204.29 |
FY | 2022 |
Przychody: | ¥3 569.01B |
Zysk brutto: | ¥2 462.16B (68.99 %) |
EPS: | ¥147.14 |
FY | 2021 |
Przychody: | ¥3 197.81B |
Zysk brutto: | ¥2 203.50B (68.91 %) |
EPS: | ¥240.72 |
Financial Reports:
No articles found.
Takeda Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥90.00 (N/A) |
¥0 (N/A) |
¥90.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥16.50 | 2000-03-28 |
Last Dividend | ¥90.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 48 | -- |
Total Paid Out | ¥3 458.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.84 | -- |
Div. Sustainability Score | 4.76 | |
Div.Growth Potential Score | 4.33 | |
Div. Directional Score | 4.54 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
7949.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7182.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
6420.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
5401.T | Ex Dividend Knight | 2023-09-28 | Annually | 0 | 0.00% | |
4410.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3593.T | Ex Dividend Knight | 2023-09-28 | Quarterly | 0 | 0.00% | |
2811.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
1429.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
9729.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8769.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0427 | 1.500 | 9.15 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0125 | 1.200 | 9.58 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0263 | 1.500 | -0.819 | -1.228 | [0.1 - 1] |
payoutRatioTTM | 1.619 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.064 | 0.800 | 9.68 | 7.74 | [1 - 3] |
quickRatioTTM | 0.465 | 0.800 | -1.972 | -1.578 | [0.8 - 2.5] |
cashRatioTTM | 0.126 | 1.500 | -0.409 | -0.614 | [0.2 - 2] |
debtRatioTTM | 0.328 | -1.500 | 4.53 | -6.80 | [0 - 0.6] |
interestCoverageTTM | 1.450 | 1.000 | -0.574 | -0.574 | [3 - 30] |
operatingCashFlowPerShareTTM | 466.22 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -82.25 | 2.00 | -10.00 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 0.692 | -1.500 | 7.23 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.675 | 1.000 | 2.08 | 2.08 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0750 | 1.000 | -0.500 | -0.500 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.157 | 1.000 | -0.240 | -0.240 | [0.2 - 2] |
assetTurnoverTTM | 0.293 | 0.800 | -1.379 | -1.103 | [0.5 - 2] |
Total Score | 4.76 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 36.00 | 1.000 | 6.47 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0263 | 2.50 | -0.526 | -1.228 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -82.25 | 2.00 | -10.00 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.60 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 466.22 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.619 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0.927 | 1.500 | 7.15 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.175 | 1.000 | 8.11 | 0 | [0.1 - 0.5] |
Total Score | 4.33 |
Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej